Your Health and Wellness Partner

Fast Acting HIV Drug Gives Hope to Women Starting HIV Treatment in Late Pregnancy

Fast Acting HIV Drug Gives Hope to Women Starting HIV Treatment in Late Pregnancy

More than 1.6 million women living with HIV become pregnant every year, and not all of them seek antiretroviral treatment, the aim of which is to improve maternal health and prevent mother-to-child-transmission (MTCT) of the infection. Without early treatment, 15-45 percent of HIV-positive pregnant women may transmit the virus to their babies. With the current treatment, HIV transmission to children can be reduced to close to zero when taken properly.

However, the concern has been the late presentation of pregnant women for HIV treatment. This study showed that a fast acting HIV drug called dolutegravir can significantly lower the risk of MTCT in pregnant women who present late.

Read more here – https://news.liverpool.ac.uk/2020/05/18/results-of-highly-significant-hiv-transmission-study-published/